Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 96, Issue 2, 2006, Pages 327-333

  Berkowitz, Robert B ^a   Braker, Susan ^a   Lutz, Cheryl ^a   Jones, Pat ^a   Meeves, Suzanne ^b   Qiu, Chunfu ^b   Varghese, Santosh T ^b   Georges, George ^b  

^a Rx Research   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FEL D 1 ALLERGEN; FEXOFENADINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ARTICLE; CAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NASAL PRURITUS; PALATE; PRIORITY JOURNAL; PROPHYLAXIS; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SINUSITIS; SNEEZING; SOMNOLENCE;

EID: 33244470411     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61243-4     Document Type: Article

References (20)

1. Gergen P, Turkeltaub P. The association of individual allergen reactivity with respiratory disease in a national sample: data from the Second National Health and Nutrition Examination Survey, 1976-80 (NHANES II). J Allergy Clin Immunol. 1992;90(pt 1):579-588.
2. Bollinger M, Eggleston P, Flanagan E, Wood R. Cat antigen in homes with and without cats may induce allergic symptoms. J Allergy Clin Immunol. 1996;97:907-914.
3. Arbes SJ, Cohn R, Yin M, et al. Dog allergen (Can f 1) and cat allergen (Fel d 1) in US homes: results from the National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol. 2004;114:111-117.
4. Stuck BA, Czajkowski J, Hagner AE, et al. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol. 2004;113:663-668.
5. Schoenwetter WF, Dupclay L Jr, Appajosyula S, et al. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin. 2004;20:305-317.
6. Phipatanakul W. Animal allergens and their control. Curr Allergy Asthma Rep. 2001;1:461-465.
7. Wood R, Chapman M, Adkinson N, Eggleston P. The effect of cat removal on allergen content in household-dust samples. J Allergy Clin Immunol. 1989;83:730-734.
8. Meltzer E, Casale T, Nathan R, Thompson A. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Clin Immunol. 1999;83:311-317.
9. van Cauwenberge P, Juniper E; STAR Study Investigating Group. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120mg, loratadine 10mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000;30:891-899.
10. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol. 2000;43(pt 1):24-30.
11. Phipatanakul W, Kesavanathan J, Eggleston P, et al. The value of acoustic rhinometry in assessing nasal responses to cat exposure. J Allergy Clin Immunol. 1998;102(pt 1):896-901.
12. Wood R, Laheri A, Eggleston P. The aerodynamic characteristics of cat allergen. Clin Exp Allergy. 1993;23:733-739.
13. Perry TT, Corren J, Philip G, et al. Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. Ann Allergy Asthma Immunol. 2004;93:431-438.
14. Phipatanakul W, Eggleston P, Conover-Walker M, et al. A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge. J Allergy Clin Immunol. 2000;105:704-710.
15. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003;111:S835-S842.
16. Phipatanakul W, Nowak-Wegrzyn A, Eggleston P, et al. The efficacy of montelukast in the treatment of cat allergen-induced asthma in children. J Allergy Clin Immunol. 2002;109:794-799.
17. Corren J, Spector S, Fuller L, et al. Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure. Ann Allergy Asthma Immunol. 2001;87:211-217.
18. Wood R, Eggleston P, The effects of intranasal steroids on nasal and pulmonary responses to cat exposure. Am J Respir Crit Care Med. 1995;151(pt 1):315-320.
19. Ciprandi G, Cosentino C, Milanese M, et al. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy. 2001;56:1068-1070.
20. Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy. 2002;32:1504-1509.